All In Biotech

NDA 212018 · Janssen Biotech

Balversa

Erdafitinib · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Oct 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Apr 12, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

39

3 Phase 3, 4 recruiting

FAERS reports

1,247

919 serious, 349 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 24, 2025.

BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. ( 1 , 2.1 ) Limitations of Use BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. ( 1 , 14.1 ) Limitations of Use BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy [see Clinical Studies (14.1) ] .

Mechanism: Erdafitinib is a kinase inhibitor that binds to and inhibits enzymatic activity of FGFR1, FGFR2, FGFR3 and FGFR4 based on in vitro data. Erdafitinib inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdafitinib demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 19, 2024 Supplement 8 · Efficacy · priority review LabelLetter
  • Jan 19, 2024 Supplement 9 · Efficacy · priority review LabelLetter
  • Apr 12, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
3 products under this application
  • BALVERSA · ERDAFITINIB 3MG · TABLET, ORAL · Prescription
  • BALVERSA · ERDAFITINIB 4MG · TABLET, ORAL · Prescription
  • BALVERSA · ERDAFITINIB 5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Erdafitinib" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death272
  • off label use104
  • diarrhoea100
  • stomatitis82
  • onycholysis58
  • fatigue53
  • hyperphosphataemia53
  • nail disorder53
  • dry mouth46
  • nail discolouration45
  • dry eye43
  • disease progression42

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
201979
2020234
2021193
2022246
2023142
2024154
2025106
202692

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Balversa (Erdafitinib)

2024 spending

$22.7M

Beneficiaries

305

1,123 claims

Per beneficiary

$74,345

$443.00 per unit

View as table
YearSpending
2020$15,867,593
2021$14,992,685
2022$16,785,721
2023$17,690,617
2024$22,675,188

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 37 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.